Amylyx Pharmaceuticals Inc (AMLX) - Net Assets
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has net assets worth $305.26 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($332.64 Million) and total liabilities ($27.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AMLX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $305.26 Million |
| % of Total Assets | 91.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.57 |
Amylyx Pharmaceuticals Inc - Net Assets Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Amylyx Pharmaceuticals Inc (AMLX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual net assets of Amylyx Pharmaceuticals Inc from 2019 to 2025. For live valuation and market cap data, see Amylyx Pharmaceuticals Inc (AMLX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $305.26 Million | +85.27% |
| 2024-12-31 | $164.76 Million | -61.99% |
| 2023-12-31 | $433.43 Million | +27.25% |
| 2022-12-31 | $340.61 Million | +325.32% |
| 2021-12-31 | $-151.17 Million | -126.55% |
| 2020-12-31 | $-66.72 Million | -163.14% |
| 2019-12-31 | $-25.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amylyx Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72579300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Comprehensive Income | $404.00K | 0.13% |
| Other Components | $1.06 Billion | 346.02% |
| Total Equity | $305.26 Million | 100.00% |
Amylyx Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
$1.77 Billion |
|
Veris Residential Inc
NYSE:VRE
|
$1.77 Billion |
|
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
|
$1.77 Billion |
|
A10 Network
NYSE:ATEN
|
$1.77 Billion |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
$1.77 Billion |
|
JetBlue Airways Corp
NASDAQ:JBLU
|
$1.77 Billion |
|
Avi Ltd
JSE:AVI
|
$1.77 Billion |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
$1.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amylyx Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 164,765,000 to 305,259,000, a change of 140,494,000 (85.3%).
- Net loss of 144,735,000 reduced equity.
- Other comprehensive income increased equity by 496,000.
- Other factors increased equity by 284,733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-144.74 Million | -47.41% |
| Other Comprehensive Income | $496.00K | +0.16% |
| Other Changes | $284.73 Million | +93.28% |
| Total Change | $- | 85.27% |
Book Value vs Market Value Analysis
This analysis compares Amylyx Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.45 | $16.01 | x |
| 2020-12-31 | $-1.18 | $16.01 | x |
| 2021-12-31 | $-2.61 | $16.01 | x |
| 2022-12-31 | $5.12 | $16.01 | x |
| 2023-12-31 | $6.19 | $16.01 | x |
| 2024-12-31 | $2.42 | $16.01 | x |
| 2025-12-31 | $3.23 | $16.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amylyx Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-47.41%) is below the historical average (-39.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -1038.99% | 0.44x | 0.00x | $-12.28 Million |
| 2020 | 0.00% | -6504.62% | 0.05x | 0.00x | $-35.61 Million |
| 2021 | 0.00% | -30834.74% | 0.00x | 0.00x | $-72.76 Million |
| 2022 | -58.24% | -892.38% | 0.06x | 1.15x | $-232.44 Million |
| 2023 | 11.37% | 12.94% | 0.74x | 1.19x | $5.93 Million |
| 2024 | -183.14% | -345.36% | 0.45x | 1.18x | $-318.22 Million |
| 2025 | -47.41% | 0.00% | 0.00x | 1.09x | $-175.26 Million |
Industry Comparison
This section compares Amylyx Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $265,165,249
- Average return on equity (ROE) among peers: -52.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc (AMLX) | $305.26 Million | 0.00% | 0.09x | $1.77 Billion |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more